Concepedia

Author

J.P. Courrèges

Laboratoire de Biotechnologie de l'Environnement

Also Known As

J Courreges, J. Courrèges, J.-P. Courreges, J.-P. Courrèges, J.P. Courreges, J.P. Courrèges, J.‐P. Courrèges, Jean-Pierre Courreges, Jean-Pierre Courrèges, Jean-Pierre Courrèges

77

Publications

1.3K

Citations

7

H-Index

0

Concepts

All Affiliations

Laboratoire de Biotechnologie de l'EnvironnementNovo Nordisk (Denmark)Aarhus University HospitalAtlanta Diabetes Associates
JC

About

J.P. Courrèges is an author at Laboratoire de Biotechnologie de l'Environnement.

J.P. Courrèges

×

4

Publications

891

Citations

4

H-Index

YearCitations

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Tina Vilsbøll, Milan Zdravkovic, T Le-Thi,

Diabetes Care

2007

467

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

Michael A. Nauck, John R. Petrie, Giorgio Sesti,

Diabetes Care

2015

219

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

Sultan Linjawi, Bruce W. Bode, Louis Chaykin,

Diabetes Therapy

2016

130

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes

Irl B. Hirsch, Bruce W. Bode, J.P. Courrèges,

Diabetes Care

2012

75

Page 1